Recently, monoclonal antibodies targeting programmed cell death protein 1 (PD-1) or its ligand (PD-L1), such as nivolumab, pembrolizumab or atezolizumab, have demonstrated improvement in overall survival (OS) and progression-free survival (PFS) in a subset of patients with metastatic or locally advanced lung cancer [3, 4]. Here, PDCD1 is linked to lung carcinoma.